Abstract Library

#4670 The efficacy of first-line combination therapy with everolimus plus lanreotide for gastroenteropancreatic neuroendocrine tumour with a poor prognostic factor: Updated and subgroup analysis of the phase III study, STARTER-NET (JCOG1901)

Introduction: Everolimus monotherapy provided a limited median progression-free survival (PFS) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), there remains a necessity for better therapeutic approaches.

Conference:

Presenting Author:

Authors: Hijioka S, Honma Y, Machida N, Mizuno N, Hamaguchi T,

Keywords: everolimus, lanreotide, PFS, RCT,

#4660 Clinical significance of interval imaging in patients with well-differentiated neuroendocrine neoplasms (NENs) receiving peptide receptor radionuclide therapy (PRRT)

Introduction: PRRT is an effective therapy for advanced NENs with SSTR-avid disease, however, the role of interval imaging in between PRRT cycles and its benefit is unknown.

Conference:

Presenting Author:

Authors: Grewal U, Patel R, Chandasekharan C,

Keywords: Peptide receptor radionuclide therapy, interval imaging, neuroendocrine tumour,

#4644 First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,

#4639 Prevalence and characteristics of incidental NET of the Meckel’s diverticula: Retrospective cohort study at a tertiary centre

Introduction: Meckel’s diverticulum is a rare finding in adults but can harbour malignancies such as leiomyosarcoma or neuroendocrine tumours (NET). The clinical presentation and tumour characteristics, including grading, have shown high variability in recent studies for NET.

Conference:

Presenting Author: Berckenhagen L

Authors: Berckenhagen L, Weidemann S, Amin T, Ritter A, Poppinga J,

Keywords: Meckel’s diverticula, incidental NET, acute abdomen, lower GI-bleeding,

#4629 Identification of putative master regulators in pancreatic neuroendocrine tumours using gene expression data and network inference

Introduction: Pancreatic neuroendocrine tumours (pNETs) are a heterogenous group of pancreatic malignancies with a unique biology and pathophysiology. Tumour grade and extension are commonly used for prognostic determination. Current pathologic grading system needs regular updates to refine prognostic classification. Genomic screening may provide more objective classes and reflect tumour biology.

Conference:

Presenting Author: Jannin A

Authors: Jannin A, Elati M, Do Cao C, Figeac M, Leteurtre E,

Keywords: pancreatic neuroendocrine tumour, RNA-Seq, Master regulators, MEN1,